Heme disposal inside heart transplants: a trigger for rejection?

Abstract

Cardiac allograft vasculopathy (CAV) is a fibroproliferative form of transplant rejection with limited treatment options other than retransplantation. In this issue, See and colleagues examined human explanted allografts with CAV. They found that a high proportion of intragraft plasma cells produce antibodies that recognize the heme catabolic end product, bilirubin. Clonotypic profiling revealed that bilirubin-reactive antibody-producing plasma cells develop from graft-infiltrating innate-like B cells, a subset often characterized by their rapid production of polyreactive natural antibodies as an early defense against infection. CAV but not nonrejecting graft tissue contained bilirubin deposits along with macrophages that expressed genes involved in heme catabolism. These findings raise the intriguing possibility that graft-derived bilirubin-specific antibodies target local heme catabolism to promote CAV.